Competitive intelligence on
small-molecule drugs and
the 80,000 global patents
covering them

Start your free trial now

No commitment — No credit card required

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: CAVERJECT IMPULSE

« Back to Dashboard

Summary for Tradename: CAVERJECT IMPULSE

Patents:1
Applicants:1
NDAs:1
Suppliers: see list2

Pharmacology for Tradename: CAVERJECT IMPULSE

Clinical Trials for: CAVERJECT IMPULSE

The Use of Prostaglandin E1 in Head and Neck Microsurgery
Status: Recruiting Condition: Microsurgery; Head and Neck; Prostaglandin E1; Thrombosis; Complications

Protective Effect of Lipo-PGE1 on Myocardial Injury Following Percutaneous Coronary Intervention
Status: Not yet recruiting Condition: Prostaglandin E1; Percutaneous Coronary Intervention

Prostaglandin E1 in Outpatients With Intermittent Claudication
Status: Completed Condition: Stage II Peripheral Arterial Occlusive Disease; Intermittent Claudication Fontaine Stage II PAOD

Alprostadil in Maculopathy Study (AIMS)
Status: Terminated Condition: Macular Degeneration

Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV
Status: Completed Condition: Peripheral Arterial Occlusive Disease

Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure
Status: Withdrawn Condition: Infant, Newborn; Respiratory Insufficiency; Pulmonary Hypertension; Respiratory Distress Syndrome, Newborn; Streptococcal Infections

Efficacy and Safety of Alprostadil Prevent Contrast Induced Nephropathy
Status: Active, not recruiting Condition: Kidney Diseases; Diabetes Mellitus; Acute Kidney Injury; Kidney Failure, Chronic; Renal Insufficiency

Efficacy, Safety and Satisfaction of VITAROS (Transdermal Topical Alprostadil) in Men With Erectile Dysfunction
Status: Withdrawn Condition: Erectile Dysfunction

Inhaled Prostaglandin E1 (IPGE1) for Hypoxemic Respiratory Failure (NHRF)
Status: Terminated Condition: Prematurity; Respiratory Insufficiency; Pulmonary Hypertension; Respiratory Distress Syndrome, Newborn

Sildenafil Citrate and Alprostadil in Treating Patients Undergoing Bilateral Nerve-Sparing Robotic-Assisted Prostatectomy for Nonmetastatic Prostate Cancer
Status: Completed Condition: Prostate Cancer; Male Erectile Disorder; Stage I Prostate Cancer; Stage II Prostate Cancer

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacia And Upjohn
CAVERJECT IMPULSE
alprostadil
INJECTABLE;INJECTION021212Jun 11, 2002RXNo5,716,338<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access , or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc